Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevenopran
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bevenopran is a peripherally acting μ-opioid receptor antagonist that also acts on δ-opioid receptors. It was developed for the treatment of chronic opioid-induced constipation (OIC). The drug works by blocking the action of opioids in the gastrointestinal tract, thereby alleviating constipation without affecting central analgesia. Bevenopran reached phase 3 clinical trials for OIC but development was discontinued before approval. The original developer was Eli Lilly and Company, with later development by Cubist Pharmaceuticals and subsequently Merck following acquisition[1][2][3][6].
- Other names
- CB-5945CB5945CB 5945
02
Targets
MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)
Beyond the preview
Go deeper on bevenopran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevenopran.